Active, not recruitingPhase 1NCT05146739
Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane
Studying Down syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Maria Luisa SulisPediatric Early Phase Clinical Trial Network
- Intervention
- Cytarabine(drug)
- Enrollment
- 8 enrolled
- Eligibility
- 17 years · All sexes
- Timeline
- 2023 – 2026
Study locations (19)
- Children's Hospital of Alabama, Birmingham, Alabama, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- UCSF Medical Center-Mission Bay, San Francisco, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
- Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
- Riley Hospital for Children, Indianapolis, Indiana, United States
- C S Mott Children's Hospital, Ann Arbor, Michigan, United States
- University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- +4 more locations on ClinicalTrials.gov
Collaborators
Children's Oncology Group · LLS PedAL LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05146739 on ClinicalTrials.govOther trials for Down syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07416201Natural History of Dysregulation and Aging of the Immune System in People With Trisomy 21 With and Without ThymectomyNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGNANCT07484464Effects of the Otago Exercise Program on Balance, Endurance, and Motor Coordination in Children With Down SyndromeRiphah International University
- RECRUITINGNANCT07296861HomeGrown: A Family-based Lifestyle Intervention to Support Healthy Development of Young Children With Down SyndromeUNC Lineberger Comprehensive Cancer Center
- RECRUITINGNCT07195253Oro-myofunctional Characteristics and Obstructive Sleep Apnea in Infants With Down SyndromeHospices Civils de Lyon
- RECRUITINGPHASE4NCT07280468Endotype DIrected Treatment for OSA in Down SyndromeUniversity of Arizona
- ENROLLING BY INVITATIONNCT07413224Qualitative Effects of AEF0217 in Down Syndrome PeopleAelis Farma
- RECRUITINGNANCT07425769Adapting RDAD for DSUniversity of Kansas Medical Center
- RECRUITINGPHASE2NCT07242638Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down SyndromeIcahn School of Medicine at Mount Sinai